Reuters
17 Aug 2026, 06:28 UTC · 1h ago
AstraZeneca to discontinue late-stage lung cancer trial for volrustomig
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
17 Aug 2026, 06:28 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
AstraZeneca is discontinuing a late-stage trial of volrustomig combined with chemotherapy for metastatic non-small cell lung cancer. — Failure or discontinuation of a late-stage trial reduces the pipeline potential and future revenue expectations for a key oncology asset.
-0.60Which stocks this story touches
The company is discontinuing a late-stage clinical trial for a lung cancer treatment.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
56m ago
